Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
19.95
+0.26 (1.32%)
Nov 18, 2026, 1:15 PM EST - Market open
Replimune Group Employees
Replimune Group had 465 employees as of March 31, 2026. The number of employees decreased by 14 or 2.92% compared to the previous year. That makes Replimune Group the 20,644th largest employer in the world and 2,728th in the United States.
Employees
465
Change (1Y)
-14
Growth (1Y)
-2.92%
Revenue / Employee
n/a
Profits / Employee
-$582,869
Market Cap
1.89B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 465 | -14 | -2.92% |
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Recursion Pharmaceuticals | 600 |
| Maravai LifeSciences Holdings | 410 |
| Vera Therapeutics | 362 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 274 |
| Lakefront Biotherapeutics NV | 196 |
| Septerna | 134 |
REPL News
- 2 days ago - Replimune price target raised to $27 from $14 at Piper Sandler - TheFly
- 20 days ago - Replimune price target raised to $31 from $19 at Leerink - TheFly
- 20 days ago - Replimune price target raised to $29 from $24 at Jefferies - TheFly
- 21 days ago - Replimune Group Earnings Call Transcript: Q2 2027 - Transcripts
- 21 days ago - Replimune Group Earnings release: Q2 2027 - Filings
- 21 days ago - Replimune Group Quarterly report: Q2 2027 - Filings
- 21 days ago - Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update - GlobeNewsWire
- 27 days ago - Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 - GlobeNewsWire